Literature DB >> 19514048

The cell surface glycoprotein CDCP1 in cancer--insights, opportunities, and challenges.

Andreas Wortmann1, Yaowu He, Elena I Deryugina, James P Quigley, John D Hooper.   

Abstract

In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) has been associated with several cancers and this cell surface molecule has been recognized both as a tumor marker and as a potential target to disrupt progression of cancer. Here we summarize what is known about CDCP1 including its structural features, expression in normal and cancerous tissues, and the in vitro experiments and studies in animal models that have provided the key insights into its potential role in tumor formation and metastasis in humans. We conclude by highlighting opportunities and challenges in targeting CDCP1 in cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514048     DOI: 10.1002/iub.198

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  40 in total

1.  The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.

Authors:  Ying Dong; Yaowu He; Leonore de Boer; M Sharon Stack; John W Lumley; Judith A Clements; John D Hooper
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

2.  The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility.

Authors:  C H Benes; G Poulogiannis; L C Cantley; S P Soltoff
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

3.  Regulation of inside-out β1-integrin activation by CDCP1.

Authors:  Sara G Pollan; Fangjin Huang; Jamie M Sperger; Joshua M Lang; Colm Morrissey; Anne E Cress; C Y Chu; Neil A Bhowmick; Sungyong You; Michael R Freeman; Danislav S Spassov; Mark M Moasser; William G Carter; Shakti Ranjan Satapathy; Kavita Shah; Beatrice S Knudsen
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

4.  Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

Authors:  Y He; A C Wu; B S Harrington; C M Davies; S J Wallace; M N Adams; J S Palmer; D K Roche; B G Hollier; T F Westbrook; H Hamidi; G E Konecny; B Winterhoff; N P Chetty; A J Crandon; N B Oliveira; C M Shannon; A V Tinker; C B Gilks; J I Coward; J W Lumley; L C Perrin; J E Armes; J D Hooper
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

5.  Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.

Authors:  Anna Moroz; Yung-Hua Wang; Jeremy M Sharib; Junnian Wei; Ning Zhao; Yangjie Huang; Zhuo Chen; Alexander J Martinko; Jie Zhuo; Shion A Lim; Lydia H Zhang; Youngho Seo; Sean Carlin; Kevin K Leung; Eric A Collisson; Kimberly S Kirkwood; James A Wells; Michael J Evans
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

6.  CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.

Authors:  Abdullah Alajati; Mariantonietta D'Ambrosio; Martina Troiani; Simone Mosole; Laura Pellegrini; Jingjing Chen; Ajinkya Revandkar; Marco Bolis; Jean-Philippe Theurillat; Ilaria Guccini; Marco Losa; Arianna Calcinotto; Gaston De Bernardis; Emiliano Pasquini; Rocco D'Antuono; Adam Sharp; Ines Figueiredo; Daniel Nava Rodrigues; Jonathan Welti; Veronica Gil; Wei Yuan; Tatjana Vlajnic; Lukas Bubendorf; Giovanna Chiorino; Letizia Gnetti; Verónica Torrano; Arkaitz Carracedo; Laura Camplese; Susumu Hirabayashi; Elena Canato; Gianfranco Pasut; Monica Montopoli; Jan Hendrik Rüschoff; Peter Wild; Holger Moch; Johann De Bono; Andrea Alimonti
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

7.  Proteomic analysis of microvesicles released by the human prostate cancer cell line PC-3.

Authors:  Kirsten Sandvig; Alicia Llorente
Journal:  Mol Cell Proteomics       Date:  2012-03-28       Impact factor: 5.911

8.  FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.

Authors:  Yan-Hong Cui; Hyeonmi Kim; Minyoung Lee; Joo Mi Yi; Rae-Kwon Kim; Nizam Uddin; Ki-Chun Yoo; Jae Hyeok Kang; Mi-Young Choi; Hyuk-Jin Cha; Ok-Seon Kwon; In-Hwa Bae; Min-Jung Kim; Neha Kaushik; Su-Jae Lee
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

9.  Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

Authors:  Yaowu He; Andreas Wortmann; Les J Burke; Janet C Reid; Mark N Adams; Ibtissam Abdul-Jabbar; James P Quigley; Richard Leduc; Daniel Kirchhofer; John D Hooper
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

10.  Evaluation of antibodies directed against human protease-activated receptor-2.

Authors:  Mark N Adams; Charles N Pagel; Eleanor J Mackie; John D Hooper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-31       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.